Status:
RECRUITING
I-125 Seeds Implantation in the Treatment of Recurrent Lung Cancer After Radiotherapy
Lead Sponsor:
Peking University Third Hospital
Conditions:
Brachytherapy
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
Patients with recurrence after radiotherapy are often encountered in clinical practice.Patients with recurrence after radiotherapy are less likely to undergo surgery or secondary radiotherapy, and the...
Detailed Description
The purpose of this study was to observe the efficacy and adverse reactions of RISI in the treatment of recurrent NSCLC after radiotherapy, and to evaluate its safety and efficacy.To explore the relat...
Eligibility Criteria
Inclusion
- (1) Age 18-75 years old
- (2) Pathological diagnosis of NSCLC, recurrence after radiotherapy, lesion diameter less than 5 cm
- (3) No systemic metastasis or metastasis, metastasis has been controlled by pre-treatment
- (4) No bleeding tendency, anticoagulant therapy and/or anti-platelet coagulant drugs should be stopped for at least one week before seed implantation
- (5) No serious or uncontrolled underlying diseases (such as severe or uncontrolled high). Blood pressure, diabetes mellitus, cardiovascular and cerebrovascular diseases and organ dysfunction, etc.
- (6) There is a suitable puncture path, which is expected to achieve the therapeutic dose
- (7) KPS \> 70 points, which is expected to be able to tolerate puncture/RISI therapy, and the expected survival time is longer than 3 months.
Exclusion
- (1) Poor basic pulmonary function with severe emphysema, bullae and interstitial pneumonia
- (2) Liquefaction and necrosis in a large area near the mediastinum or focus, with high risk of puncture bleeding or poor seeds distribution
- (3) Infection and ulcer in puncture site
- (4) Pregnant women, lactating women, children and psychiatric patients
- (5) Patients who are participating in other clinical studies
- (6) Poor compliance, unable to complete the treatment
- (7) The researchers think that it is not appropriate to participate in this clinical trial
Key Trial Info
Start Date :
May 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04071418
Start Date
May 1 2020
End Date
April 30 2026
Last Update
December 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Peking University Third Hospital
Beijing, Beijing Municipality, China, 100191